Skip to content

Author

R. Fortner

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Ovarian Cancer Survival Across the Introduction of Targeted Treatment: A Nationwide Analysis by Histotype and Stage

Background Bevacizumab was approved for targeted therapy of ovarian cancer in 2011 by the European Medicines Agency, with the subsequent introduction of PARP (poly[ADP]-ribose polymerase) inhibitors in 2014. Improvements in outcomes of cytoreductive surgery occurred in parallel in many regions. Objectives Population...

S. Mignozzi, Victoria Cooley, C. B. Trewin-Nybråten et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.